Intravenous immunoglobulin for chronic inflammatory demyelinating polyneuropathy: Clinical- and cost-effectiveness analyses
Gaebel K, Blackhouse G, Campbell K, Robertson D, Xie F, Assasi N, Chalk C, Levine M, Giacomini M, Goeree R
Record ID 32010001778
English
Authors' recommendations:
Compared with placebo, IVIg statistically significantly reduces impairment and disability in patients with CIDP. The improvements are similar to those resulting from corticosteroid and plasma exchange therapy. Compared with active comparators, however, it is unclear whether IVIg has therapeutic advantages in the management of CIDP. The cost per QALY of IVIg compared with corticosteroids for CIDP treatment ($549,449) is higher than what might be viewed as a cost-effective use of health care resources.
Details
Project Status:
Completed
Year Published:
2009
URL for published report:
http://www.cadth.ca/index.php/en/hta/reports-publications/search/publication/891
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Immunologic Factors
- Immunosuppressive Agents
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.